ASX:CSLBiotechs
Does CSL (ASX:CSL)'s Pediatric ANDEMBRY Win Reveal a Deeper Rare-Disease Strategy Shift?
CSL recently reported positive top-line Phase 3b results for ANDEMBRY (garadacimab-gxii) in children aged 2 to 11 with hereditary angioedema, showing a safety profile in line with earlier studies and that most participants remained attack-free over 12 months.
The company now plans regulatory filings to extend ANDEMBRY’s indication to younger children, potentially widening treatment options in a part of the HAE population where approved long-term prophylactic choices remain limited.
We’ll now...